4.7600 0.00 (0.00%)
After hours: 4:07PM EST
|Bid||4.7300 x 3200|
|Ask||4.8000 x 1300|
|Day's Range||4.7400 - 4.8600|
|52 Week Range||2.5300 - 5.1300|
|Beta (3Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In this article we are going to estimate the intrinsic value of Antares Pharma, Inc. (NASDAQ:ATRS) by taking the...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
Antares Pharma, Inc.'s (NASDAQ:ATRS): Antares Pharma, Inc. focuses on developing and commercializing self-administered...
We at Insider Monkey have gone over 738 13F filings that hedge funds and famous value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article we look at what those investors think of Antares Pharma Inc (NASDAQ:ATRS). Is Antares […]
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
On a per-share basis, the Ewing, New Jersey-based company said it had a loss of 3 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Bob Apple has been the CEO of Antares Pharma, Inc. (NASDAQ:ATRS) since 2016. This report will, first, examine the...
Antares Pharma Inc is a specialty pharmaceutical company. Antares Pharma Inc had annual average EBITDA growth of 5.50% over the past five years. Warning! GuruFocus has detected 4 Warning Signs with ATRS.
While small-cap stocks, such as Antares Pharma, Inc. (NASDAQ:ATRS) with its market cap of US$484m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...
If you want to know who really controls Antares Pharma, Inc. (NASDAQ:ATRS), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in Read More...